Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms

被引:5
作者
Mooney, Michael A. [1 ]
Simon, Elias D. [1 ]
Little, Andrew S. [1 ]
机构
[1] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA
来源
FRONTIERS IN SURGERY | 2016年 / 3卷
关键词
acromegaly; Cushing disease; endonasal; pituitary adenoma; transsphenoidal;
D O I
10.3389/fsurg.2016.00045
中图分类号
R61 [外科手术学];
学科分类号
摘要
The current treatment of pituitary adenomas requires a balance of conservative management, surgical resection, and in select tumor types, molecular therapy. Acromegaly treatment is an evolving field where our understanding of molecular targets and drug therapies has improved treatment options for patients with excess growth hormone levels. We highlight the use of molecular therapies in this disease process and advances in this field, which may represent a paradigm shift for the future of pituitary adenoma treatment.
引用
收藏
页数:7
相关论文
共 69 条
  • [1] Cabergoline in the treatment of acromegaly: A study in 64 patients
    Abs, R
    Verhelst, J
    Maiter, D
    Van Acker, K
    Nobels, F
    Coolens, JL
    Mahler, C
    Beckers, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) : 374 - 378
  • [2] Surgical Interventions and Medical Treatments in Treatment-Naive Patients With Acromegaly: Systematic Review and Meta-Analysis
    Abu Dabrh, Abd Moain
    Mohammed, Khaled
    Asi, Noor
    Farah, Wigdan H.
    Wang, Zhen
    Farah, Magdoleen H.
    Prokop, Larry J.
    Katznelson, Laurence
    Murad, Mohammad Hassan
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11) : 4003 - 4014
  • [3] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
    Amato, G
    Mazziotti, G
    Rotondi, M
    Iorio, S
    Doga, M
    Sorvillo, F
    Manganella, G
    Di Salle, F
    Giustina, A
    Carella, C
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 56 (01) : 65 - 71
  • [4] Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas
    Aveanu, A. S.
    Jaquet, P.
    Brue, T.
    Barher, A.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 286 (1-2) : 206 - 213
  • [5] LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
    Bertagna, Xavier
    Pivonello, Rosario
    Fleseriu, Maria
    Zhang, Yiming
    Robinson, Paul
    Taylor, Ann
    Watson, Catherine E.
    Maldonado, Mario
    Hamrahian, Amir H.
    Boscaro, Marco
    Biller, Beverly M. K.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (04) : 1375 - 1383
  • [6] The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly
    Bhayana, S
    Booth, GL
    Asa, SL
    Kovacs, K
    Ezzat, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) : 6290 - 6295
  • [7] Ten-year follow-up results of transsphenoidal microsurgery in acromegaly
    Biermasz, NR
    Van Dulken, H
    Roelfsema, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) : 4596 - 4602
  • [8] Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment
    Brabant, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 : S15 - S20
  • [9] Acromegaly: Molecular expression of somatostatin receptor subtypes and treatment outcome
    Bronstein, Marcello D.
    [J]. PITUITARY TODAY: MOLECULAR, PHYSIOLOGICAL AND CLINICAL ASPECTS, 2006, 35 : 129 - 134
  • [10] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    Bruns, C
    Lewis, I
    Briner, U
    Meno-Tetang, G
    Weckbecker, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) : 707 - 716